Skip to main content

Animations

MJFF Publications

5531 - 5540 of 8808 Results
Title
Year
  • Year
  • 2021
  • 2021
  • 2021
  • 2021
  • 2022
  • 2021
  • 2016
  • 2017
  • 2020
  • 2021
  • Summary Details
    OPEN
    Title: White matter hyperintensities mediate the impact of amyloid ß on future freezing of gait in Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.02.031
    Citation Count: 14
  • Summary Details
    OPEN
    Title: Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.012
    Citation Count: 19
  • Summary Details
    OPEN
    Title: Plasma NfL, clinical subtypes and motor progression in Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.016
    Citation Count: 45
  • Summary Details
    RESTRICTED
    Title: Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approach
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.05.011
    Citation Count: 19
  • Summary Details
    RESTRICTED
    Title: Deciphering the molecular mechanism and crosstalk between Parkinson's disease and breast cancer through multi-omics and drug repurposing approach
    Journal Name: Neuropeptides
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.npep.2022.102283
    Citation Count: 9
  • Summary Details
    RESTRICTED
    Title: Combined 5-HT2A and mGlu2 modulation for the treatment of dyskinesia and psychosis in Parkinson's disease
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2021.108465
    Citation Count: 17
  • Summary Details
    OPEN
    Title: Association ofGBAMutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease
    Journal Name: JAMA Neurology
    Publisher: American Medical Association (AMA)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1001/jamaneurol.2016.2245
    Citation Count: 213
  • Summary Details
    OPEN
    Title: Combining clinical and biofluid markers for early Parkinson's disease detection
    Journal Name: Annals of Clinical and Translational Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/acn3.509
    Citation Count: 10
  • Summary Details
    OPEN
    Title: How firms undertake organizational changes to shift to more-exploratory strategies: A process perspective
    Journal Name: Research Policy
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.respol.2020.104118
    Citation Count: 22
  • Summary Details
    RESTRICTED
    Title: Optimal Treatment of Depression and Anxiety in Parkinson's Disease
    Journal Name: The American Journal of Geriatric Psychiatry
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.jagp.2021.02.037
    Citation Count: 53
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.